More News! 11 Oct 2022First patient dosed in study of idiopathic pulmonary fibrosis Redx, a clinical-stage biotech company, is trialing RXC007, a wholly owned rho associated coiled-coil containing protein kinase 2 (ROCK2) selective… October 11, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022Redx presents data confirming anti-fibrotic effects of lung disease drug Redx Pharma has announced preclinical efficacy data in immune mediated models for RXC007. The data on RXC007, its lead fibrosis… October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email